PMA P940034S008
- Device
- GEN-PROBE(R) AMPLIFIED(TM) MYCOBACTERIUM TUBERCULOSIS DIRECT (MTD) TEST
- Applicant
- Gen-Probe, Inc.
- PMA number
- P940034
- Supplement
- S008
- Decision date
- 1999-09-30
- Approval order statement
- This device, a target-amplified nucleic acid probe test, is indicated for: the in vitro diagnostic detection of Mycobacterium tuberculosis complex rRNA in acid-fast bacilli (AFB) smear positive and negative concentrated sediments prepared from sputum (induced or expectorated), bronchial specimens (e.g., bronchalveolar lavages or bronchial aspirates) or tracheal aspirates. The MTD test is intended for use only with specimens from patients showing signs and symptoms consistent with active pulmonary tuberculosis. MTD is to be used as an adjunctive test for evaluating either AFB smear positive or negative sediments prepared using NALC-NaOH digestion-decontamination of respiratory specimens. Patients who are suspected of having pulmonary TB based on clinical evaluation and who have received no antituberculous therapy, less than 7 days of such therapy, or have not received such therapy in the last 12 months may be evaluated with this test. The MTD test should be performed only in laboratories proficient in the culture and identification of M.tuberculosis (Level II and III or extent 3 and 4). The MTD test must be performed in conjunction with mycobacterial culture.
- Summary
- <a href="http://www.accessdata.fda.gov/cdrh_docs/pdf/P940034S008B.pdf" target="_new">Summary of Safety and Effectiveness</a>
Current openFDA PMA Record#
- Device
- GEN-PROBE(R) AMPLIFIED(TM) MYCOBACTERIUM TUBERCULOSIS DIRECT (MTD) TEST
- Applicant
- Gen-Probe, Inc.
- PMA number
- P940034
- Supplement
- S008
- Decision date
- 1999-09-30
- Decision code
- APPR
- Date received
- 1998-09-04
- Supplement type
- Panel Track
- Supplement reason
- Labeling Change - Indications/instructions/shelf life/tradename
- Approval order statement
- This device, a target-amplified nucleic acid probe test, is indicated for: the in vitro diagnostic detection of Mycobacterium tuberculosis complex rRNA in acid-fast bacilli (AFB) smear positive and negative concentrated sediments prepared from sputum (induced or expectorated), bronchial specimens (e.g., bronchalveolar lavages or bronchial aspirates) or tracheal aspirates. The MTD test is intended for use only with specimens from patients showing signs and symptoms consistent with active pulmonary tuberculosis. MTD is to be used as an adjunctive test for evaluating either AFB smear positive or negative sediments prepared using NALC-NaOH digestion-decontamination of respiratory specimens. Patients who are suspected of having pulmonary TB based on clinical evaluation and who have received no antituberculous therapy, less than 7 days of such therapy, or have not received such therapy in the last 12 months may be evaluated with this test. The MTD test should be performed only in laboratories proficient in the culture and identification of M.tuberculosis (Level II and III or extent 3 and 4). The MTD test must be performed in conjunction with mycobacterial culture.